Bank of Nova Scotia
ALLO icon

Bank of Nova Scotia’s Allogene Therapeutics ALLO Stock Holding History

Bank of Nova Scotia’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,182
Closed -$519K – 1201
2021
Q3 		$519K Buy
20,182
+895
+5% +$21.2K ﹤0.01% 989
2021
Q2 		$503K Buy
+19,287
New +$550K ﹤0.01% 980

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of Nova Scotia's ALLO Position: Q4 2021 in Review

Bank of Nova Scotia sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 20,182 shares — an estimated $519K sold.

Bank of Nova Scotia first reported a position in ALLO in Q2 2021 and held it in 2 quarters. The position peaked at $519K in Q3 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Bank of Nova Scotia reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bank of Nova Scotia sold 20,182 Allogene Therapeutics shares in Q4 2021, an estimated $519K.
  • Bank of Nova Scotia first reported a position in Allogene Therapeutics in Q2 2021 and held it in 2 quarters.
  • Bank of Nova Scotia's Allogene Therapeutics position peaked at $519K in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Bank of Nova Scotia's 13F filing for Q4 2021, filed 11 Feb 2022.